

# **What is the association between inhaled corticosteroid use and risk of A&E attendance or death from COVID-19?**

## **Study Protocol**

**Version:** v1.0

**Date:** 13th of May 2020

This is a collaboration between the following institutions as part of openSAFELY.org:

- The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
- Electronic Health Records Research Group, Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine

## **Introduction**

The outbreak of a novel coronavirus, SARS-Cov-2, in Wuhan, China in early December 2019 has developed into a global pandemic of unprecedented scale and consequence. As of the 8<sup>th</sup> of May 2020, almost 4 million people had been infected worldwide; approximately 270,000 people died of the disease the virus causes – COVID-19<sup>1</sup>. In England cases have also grown dramatically since the start of the outbreak, with more than 200,000 people having laboratory confirmed infections, of whom more than 30,000 have died<sup>2</sup>. Early descriptive data suggest that patients with more severe COVID-19 outcomes – hospitalisation or death – tend to be older and have pre-existing comorbidities<sup>3-6</sup>. In particular, descriptions of patients in China suggested hypertension, cardiovascular disease and diabetes were more common among patients with severe disease<sup>3</sup>, although these did not take into account differences in age or gender among patients with or without severe disease.

As SARS-Cov-2 is a respiratory virus, it might be expected that patients with pre-existing respiratory conditions – such as chronic obstructive pulmonary disease (COPD) and asthma – would be particularly susceptible to infection, and once infected, that they would also tend to experience worse outcomes. However, rather surprisingly, early reports of COVID-19 patient characteristics described a very low prevalence of pre-existing respiratory conditions<sup>3,7</sup>. A descriptive study of 140 hospitalised COVID-19 patients in Wuhan found a COPD prevalence of 1.4%, whereas Guan et al's description of 1,099 outpatient and inpatient COVID-19 patients in the same area found a COPD prevalence of 1.1%<sup>3,8</sup>. Early analyses of the first few hundred cases in the UK also found an unexpected protective effect of asthma (McDonald 2020, personal communication), and whilst our research collaboration found an association between asthma and hospital death from COVID-19 using the OpenSAFELY platform, the effect size was surprisingly modest<sup>6</sup>. Although other data from the UK and US have since reported prevalences of respiratory conditions that are closer to

expectations<sup>5,9</sup>, the early data from Wuhan led to speculations that some treatments used in chronic respiratory diseases, specifically inhaled corticosteroids (ICS), may have a protective effect against SARS-CoV-2 infection or the development of symptoms that lead to diagnosis<sup>7,10</sup>

Inhaled corticosteroids (ICS) are glucocorticoids that are used to reduce inflammation, oedema, and mucus secretions in the airways and lungs. They have four main effects; anti-inflammatory, immunosuppressive, anti-proliferative/anti-mitotic and vasoconstrictive<sup>11</sup>. Although they cause less systemic effects than oral steroids they are associated with a higher risk of pneumonia in COPD<sup>12–14</sup>. Systemic steroid adverse effects, such as adrenal suppression may occur, if high doses are prescribed for a long time. Recent evidence from an in-vitro study has indicated that a specific ICS (Ciclesonide) can suppress the replication of SARS-CoV-2<sup>15</sup>, and one other ICS in combination therapy with other medication, (budesonide in combination with glycopyrronium and formoterol) has been shown to inhibit the production of cytokines after cells were exposed to HCoV-229E, another human coronavirus<sup>16</sup>. A recent rapid review of the role of ICS in SARS-COV-2, SARS-COV-1, and MERS did not find any studies investigating the impact of prior ICS use on outcomes in either infection<sup>10</sup>. It is currently uncertain whether ICS influence the risk of developing COVID-19, either by increasing or decreasing it, and, once infected, whether ICS can affect the clinical prognosis of COVID-19 disease<sup>10</sup>.

Epidemiological data investigating this hypothesis is scarce, although there are two ongoing randomised controlled trials investigating the role of ICS in patients hospitalised with laboratory confirmed COVID-19 and mild COVID-19 respectively<sup>17,18</sup>. Results from these trials are not expected to become available for some time with estimated study completion dates of July and Sept 2020 respectively, and, regardless of their findings, they will not answer questions related to the impact of long-term regular use of ICS. Further insights into the role of ICS use in COVID-19 may be gained from well-designed analyses of routinely collected electronic health record data. We therefore set out to explore the impact of recent ICS use on outcomes in COVID-19 disease using linked data from over 17 million patients in England.

## Objectives

The specific objectives of the study are:

### **Primary Objectives**

1. Estimate the effect of ICS use on the risk of death due to COVID-19 adjusting for confounding variables, among people with COPD living in England.
2. Estimate the effect of ICS use on the risk of death due to COVID-19 adjusting for confounding variables, among people with asthma living in England.

### **Secondary Objectives**

1. Estimate the effect of ICS use and risk of the following outcomes due to COVID-19 among people with COPD living in England.
  - a. A&E attendance due to suspected/definite COVID-19
2. Estimate the effect of ICS use and risk of the following outcomes due to COVID-19 among people with asthma living in England:

- a. A&E attendance due to suspected/definite COVID-19

Initially, results for the primary objective only will be presented. Further development work is ongoing to understand the data required to define the secondary outcome reliant on A&E attendance

### ***Exploratory Objectives***

1. If either a positive or negative effect of ICS use is found, use quantitative bias analysis to quantify the strength of unmeasured confounding that would need to be present for the association to have been solely explained by unmeasured confounding.
2. Evaluate how any association between ICS use and death due to COVID-19 varies by estimated ICS adherence.
3. If either a positive or a negative effect of ICS use is found, we will explore the possibility of re-running analyses using a negative control outcome - preliminarily Influenza-Like-Illness (ILI).

## **Methods**

### ***Data Source***

We will use data from general practice (GP) records, obtained from the GP software provider The Phoenix Partnership (TPP), linked to COVID-19 inpatient hospital death notifications. The data will be accessed, linked and analysed through OpenSAFELY.org - a new data analytics platform created to address urgent questions relating to the epidemiology and treatment of COVID-19 in England, hosted by TPP. OpenSAFELY provides a secure software interface that allows NHS records to be pseudonymised, linked and analysed in near real-time; the GP patient data held on OpenSAFELY never leaves TPP's secure environment; other datasets are linked to it.

The research dataset analysed through OpenSAFELY is based on GP records retrieved from the TPP SystmOne electronic health record system. These data include diagnoses, medicines, physiological parameters, such as body mass index and vital signs, prior investigations, such as blood test results, and basic sociodemographics for almost 24 million individuals – approximately 40% of the English population. Data extracted by TPP SystmOne have previously been used in medical research, as part of the ResearchOne dataset. These records were subsequently linked to data from a number of other organisations who were directed under the Health Service (Control of Patient Information) Regulations 2002 to make their data available for COVID-19 research with the openSAFELY initiative. Currently, linkage is possible to: (1) the NHSE/NHSX Emergency Care Data Set (ECDS), which contains data on emergency attendance at A&E clinics across England; (2) the NHSE/NHSX Second Generation Surveillance System (SGSS) data on SARS-COV-2 test results; (3) the Intensive Care National Audit & Research Centre (ICNARC) Case Mix Programme, containing data on COVID-19 related Intensive Treatment Units (ITU) admissions; (4) the NHSE/NHSX COVID-19 Patient Notification System (CPNS) data on deaths among COVID-19 inpatients occurring in hospitals; and (5) Office for National Statistics (ONS) death data, which includes information on all deaths, including those due to non-COVID-19 causes as well as those occurring outside the hospital setting.

All data is held in a secure research environment hosted by TPP, which is a Tier 3 data centre, accredited to NHS Digital standards for centrally hosted clinical systems (ISO 27001 standard and IG Toolkit version 2).

### ***Study Design and Population***

We will use a population based cohort design to address our research questions. Patients will be followed from the 1st of March 2020, considered the start of risk for experiencing the outcomes due to the dynamics of the coronavirus outbreak in the UK, until the last date of data availability. Patients who do not experience the outcome of interest will be censored at the last date of CPNS data availability, death due to other causes recorded in ONS, or the date patients are transferred away from TPP, whichever comes first. Due to a reporting delay in ONS, the censoring information for deaths due to other causes will be subject to an approximately seven day lag, however, the impact of this delay on the analyses is anticipated to be small.

From the raw data, we will select two cohorts with asthma or COPD, as follows:

#### ***Cohort 1: Asthma***

Individuals meeting the following criteria will be included:

##### ***Inclusion criteria:***

1. A record of asthma in the TPP primary care record within 3 years prior to 1st of March 2020. This approach has been used to identify patients with asthma in recent work based on clinical respiratory and electronic health record (EHR) research experience within the study team<sup>19,20</sup>. Recently coded illness was considered to be a reliable way of identifying currently active disease and avoids including people with earlier misdiagnosed disease.
2.  $\geq 18$  years of age and  $\leq 110$  years of age at the 1st of March 2020
3. Recorded male or female gender in TPP primary care record at the 1st of March 2020

##### ***Exclusion criteria***

1. Less than 12 months of primary care records whilst registered in a TPP practice available at the 1st of March 2020, which may preclude adequate characterisation of potentially important confounding variables and recording of asthma.
2. A diagnosis of COPD or other chronic respiratory conditions within 3 years prior to 1st of March 2020.
3. Receiving nebulised asthma medication in the last 12 months. This tends to represent more severe disease; these patients were excluded to help assemble a more homogeneous population.
4. A very small number of patients (<1%) are anticipated to have a missing Index of multiple deprivation (IMD) status and will be excluded from the analysis.

## *Cohort 2: COPD*

Individuals meeting the following criteria will be included

### *Inclusion criteria:*

1. A diagnosis of COPD in the TPP primary care record any time prior to 1st of March 2020.
2.  $\geq 35$  years of age and  $\leq 110$  years of age at the 1st of March 2020 (representing older profile of COPD patients)
3. Recorded male or female gender in TPP primary care record at the 1st of March 2020
4. Record of ever smoking (either current or past) prior to 1st of March 2020

The additional inclusion criterion requiring people with COPD to have a record of smoking was taken as we anticipated there to be a number of inaccurate COPD diagnostic codes; a diagnostic code in combination with a smoking record was considered the most reliable way to identify people with COPD.


### *Exclusion criteria*

1. Less than 12 months of primary care records available whilst registered in a TPP practice at the 1st of March 2020, which would preclude adequate characterisation of potentially important confounding variables.
2. Diagnosis of asthma or other chronic respiratory conditions in the 3 years prior to 1st Mar 2020
3. Receiving nebulised COPD medication in last 12 months. This tends to represent more severe disease and is excluded to help assemble a more homogeneous population.
4. A very small number of patients (<1%) are anticipated to have missing Index of multiple deprivation (IMD) status and will be excluded from the analysis

Note: for both asthma and COPD populations, expected exclusions due to recorded diagnosis of both asthma and COPD is ~14%, and the exclusion due to more than one other chronic respiratory condition is expected to be low.

The inclusion and exclusion criteria are illustrated in Figure 1.

**Figure 1: Illustration of the Study Design**



## Study Measures

Discussions and decisions on every measure have been documented before implementing the final underlying code to complete the analysis. Detailed information on compilation and sources for every individual codelist is available at <https://codelists.opensafely.org/> and the lists are available for inspection and re-use by the broader research community.

## Exposure

The exposure of interest is the category of asthma/COPD medication prescribed in the 4 months prior to 1st Mar 2020 to capture usage in normal conditions. This date was chosen due to reports of substantial early and over-ordering of medicines and appeals by the NHS not to extend prescription durations in March. Therefore prescribing patterns from March may not represent usual usage e.g. with respect to levels of adherence. To investigate the impact of ICS use we need to compare against non-ICS treatment in both asthma and COPD. Specific exposure categories of interest are defined as follows:

## COPD Exposures

There is some degree of treatment choice between ICS and non-ICS based therapies based on current NICE guidelines<sup>21</sup> and with this in mind, the primary definition for treatment categories is shown in Table 1. As with asthma, patients receiving either no treatment, or no LAMA, LABA or ICS therapy will be described but will be excluded from the comparative analyses:

**Table 1. Operational Definition for the COPD Drug Exposure of Interest**

Variable	Variable level	Category	Definition	Timeframe

Drug Exposure	0	Non-ICS based therapy (LABA/LAMA)	<p>Meeting both criteria:</p> <p>1 At least one prescription in the LABA-LAMA combination list:</p> <p><a href="https://codelists.opensafely.org/codelist/opensafely/lab-lama-combination-inhaler/">https://codelists.opensafely.org/codelist/opensafely/lab-lama-combination-inhaler/</a></p> <p>OR</p> <p>(at least one prescription of LABA</p> <p><a href="https://codelists.opensafely.org/codelist/opensafely/single-ingredient-laba-inhalers/">https://codelists.opensafely.org/codelist/opensafely/single-ingredient-laba-inhalers/</a></p> <p>AND at least one prescription of LAMA</p> <p><a href="https://codelists.opensafely.org/codelist/opensafely/single-ingredient-lama-inhalers/">https://codelists.opensafely.org/codelist/opensafely/single-ingredient-lama-inhalers/</a> )</p> <p>2. No prescription for an ICS in the 4 months to 29 Feb 2020</p>	4 months prior to 1st Mar 2020.
	1	ICS based combination therapy	<p>Any COPD therapy that includes an ICS, in single or combination product in the 4 months to 29 Feb 2020 and meeting one of the following criteria:</p> <p>1. Any prescription for a LABA+LAMA+ICS combination product</p> <p><a href="https://codelists.opensafely.org/codelist/opensafely/lab-lama-ics-combination-inhaler/">https://codelists.opensafely.org/codelist/opensafely/lab-lama-ics-combination-inhaler/</a></p> <p>2. Any prescription for a LABA+ICS combination product</p> <p><a href="https://codelists.opensafely.org/codelist/opensafely/lab-lama-ics-combination-inhaler/">https://codelists.opensafely.org/codelist/opensafely/lab-lama-ics-combination-inhaler/</a></p>	

			<a href="https://codelists.opensafely.org/codelist/opensafely/lab-lama-combination-inhaler/">fely/lab-lama-combination-inhaler/</a> 3. Any prescription for a single constituent ICS product AND (a prescription for a single constituent LABA or a prescription for a combination LAMA + LABA) <a href="https://codelists.opensafely.org/codelist/opensafely/high-dose-ics-inhalers/">https://codelists.opensafely.org/codelist/opensafely/high-dose-ics-inhalers/</a> <a href="https://codelists.opensafely.org/codelist/opensafely/low-and-medium-dose-ics-inhalers/">https://codelists.opensafely.org/codelist/opensafely/low-and-medium-dose-ics-inhalers/</a> <a href="https://codelists.opensafely.org/codelist/opensafely/single-ingredient-lab-inhalers/">https://codelists.opensafely.org/codelist/opensafely/single-ingredient-lab-inhalers/</a> <a href="https://codelists.opensafely.org/codelist/opensafely/lab-lama-combination-inhaler/">https://codelists.opensafely.org/codelist/opensafely/lab-lama-combination-inhaler/</a>	
--	--	--	--	--

In COPD, people commonly receive two or more treatments, and the exposure of interest is any combination of therapy containing ICS. A further secondary exposure definition for COPD treatment is as follows, separating out patients on dual and triple therapy containing an ICS

- Non-ICS based treatment (baseline)
- ICS based dual therapy (LABA + ICS)
- ICS based triple therapy (LABA + LAMA + ICS)

### Asthma Exposures

The primary exposure definition will be largely based on the ICS treatment pathway in current British Thoracic Society (BTS) treatment guidelines for adult asthma<sup>22</sup>. The strength of individual ICS products will be categorised according to current BTS guidance

All respiratory medications prescribed in the 4 months leading up to 1st Mar 2020 will be ascertained and used to categorise treatments as summarised in Table 2. Any other non-ICS asthma therapy is permitted in all categories except the baseline which is defined as SABA only. We acknowledge that patients in the baseline group may differ in important ways from those prescribed ICS but are anticipating some degree of comparability based on respiratory disease clinical treatment experience within the study team. Furthermore, the stratification of ICS dose will help explore possible dose related patterns. Patients receiving



no treatment for asthma will be described regarding baseline characteristics but will not be included in the comparative analyses, .

Links are provided to the OpenSAFELY.org hosted codelists (OpenCodelists) for these variables. In the first planned analysis, we have analysed based on the product strength that has been prescribed. Likely dose taken is not simple to derive from the data, as dose syntax e.g. *Inhale one puff twice daily* is not readily available. Low and medium are grouped together due to overlap with higher strength products being easier to distinguish using this method.

**Table 2. Operational Definition for the Asthma Drug Exposure of Interest**

Variable	Variable level	Category	Definition	Timeframe
Drug Exposure	0	SABA only	Receiving a SABA, AND not receiving a LABA, ICS, or LTRA, singly or in combination in the 4 months to 29 Feb 2020.  Prescription for any drug in the following category:  <a href="#">Links to OpenCodelists definition</a>	4 months prior to 1st Mar 2020.
	1	Low/medium dose ICS based therapy	Receiving a low/medium dose ICS with or without SABA, LABA, LTRA, singly or in combination in the 4 months to 29 Feb 2020:  <a href="#">Links to OpenCodelists definition</a>	
	2	High dose ICS based therapy	Receiving a high dose ICS with or without SABA, LABA, LTRA, singly or in combination in the 4 months to 29 Feb 2020:  <a href="#">Links to OpenCodelists Definition of high dose ICS</a>	

If patients have prescriptions for both low and medium/high ICS dose therapy, they will be categorised as receiving the most recent one. In a sensitivity analysis, these patients will be classified as receiving high-dose ICS.

## Follow up and Outcomes

Follow up for each cohort will begin on 1st Mar 2020 and end at the latest of the outcome of interest in each analysis, and the date of last data availability. The primary outcome is death occurring among inpatients hospitalised with laboratory confirmed COVID-19 in the CPNS dataset, due to data availability. The secondary outcomes is presenting at an emergency unit with suspected or confirmed COVID-19 (ECDS data)

An operational definition for the primary outcome is provided in Table 3.

**Table 3. Operational Definition for the Primary Outcome Variable**

Variable	Definition	Timeframe
COVID-19 Death	<p>Death information from CPNS will be used to capture deaths occurring among inpatients with laboratory confirmed COVID-19. Date of death will be defined from a single DateOfDeath variable in this dataset. The event date is defined as the death date.</p> <p><a href="#">Github CPNS death Description</a></p> <p>ONS dates of death will be ignored for the construction of the event date; ONS death dates will instead be used for censoring dates. Therefore, people who have a potentially conflicting ONS date of death that's earlier than their CPNS death will be censored at their ONS death date for these analyses and the death will not be included as an outcome. Individuals with an ONS date of death that's later than their CPNS death will be considered as having died at their CPNS death date.</p>	On or after the 1 <sup>st</sup> of March 2020 until the end of data availability

The diagnostic codes that will be used to identify the secondary, COVID-19 specific, outcomes are shown below, and all code (including early versions) for identifying these outcomes will be made public in the study github repository.

ICD-10 codes will be used to identify COVID-19 related outcomes in ONS:

- U071 COVID-19, virus identified
- U072 COVID-19, virus not identified

SNOMED codes to identify confirmed, suspected and probably COVID-19 disease in ECDS are yet to be determined.

## Covariates

The covariates of interest were chosen following discussion with practising clinicians to identify potential important determinants of our exposure of interest (choice of asthma/COPD drug) and the outcomes of interest. The covariates which were pre-specified as potentially important confounding variables are listed below. Definitions and code lists are available at

<https://codelists.opensafely.org/> and are available for inspection and re-use by the broader research community.

Unless otherwise specified, variables were created using diagnostic codes present ever in a patients' medical record.

- Age as of the 1st of March 2020
- Sex
- Ethnicity
- BMI, ascertained from weight measurements within the last 10 years, restricted to those taken when the patient was over 16 years old
- Smoking, most recent code prior to 1st of March 2020 (asthma only, as included by definition in COPD)
- Hypertension, using diagnostic codes only
- Heart Failure
- Other Heart Disease
- Diabetes
- Cancer
- Immunosuppression, including organ transplant, sickle cell anaemia and splenectomy
- Chronic Kidney Disease, using creatinine measurements within the year prior to the 1st of March 2020 OR ever having a code for renal dialysis
- GP consultation rate in the year prior to index dichotomized as 0 or  $\geq 1$
- Flu vaccination status, between 1st Sep 2019 and 1st Mar 2020
- Pneumococcal vaccination status, 5 years prior to 01 Mar 2020
- Current Statin use, within 4 months of 1st of March 2020
- Current Insulin use, within 4 months of 1st of March 2020
- Current Oral Steroid use, within 4 months of 1st of March 2020
- Index of Multiple Deprivation
- Geographic region
- COPD only:
  - Exacerbation history in the year prior to index - identified using a validated algorithm (Rothnie et al, 2015).
  - Prior history of asthma
- Asthma only: Exacerbation history in the year prior to index - identified using the process adopted by Bloom et al for moderate exacerbations identified using primary care records only [19].

## Missing Data

In the primary analysis, those with missing BMI will be assumed non-obese and those with missing smoking information will be assumed to be non-smokers on the assumption that both obesity and smoking would be more likely to be recorded if present. We anticipate ~25% missing data on ethnicity and will exclude this variable from the primary models. A sensitivity analysis will be done amongst people with recorded ethnicity, adjusting for this variable in addition to the others. We anticipate ~5% missing data on GP consultation rate and will add this variable into a sensitivity analysis amongst those with complete recording of this variable.

## Statistical Analysis

### Primary Objectives

As a first step, flowcharts showing the number of patients meeting each inclusion and exclusion criteria for the cohorts will be generated. The characteristics of patients in each cohort will be summarised using descriptive statistics, stratified by exposure status<sup>25</sup>.

Time to the primary outcome, in-hospital death due to COVID-19 as registered in CPNS, will be displayed in Kaplan-Meier plots with time in study as the timescale. Cox regression will be used to estimate hazard ratios and 95% confidence intervals for the association between the categories in the drug class exposure variable and the outcome. Univariable models, models adjusted for age and sex as well as fully adjusted models, including all of the confounders listed in the covariates list, will be presented. Graphical methods and tests based on Schoenfeld residuals will be used to explore violations of the proportional hazards assumption. Post-hoc models including other adjustments, or removing some adjustment variables may be fit however, these will be clearly marked as post-hoc exploratory work in the presentation of any results. *A priori* we will determine whether the association between ICS exposure and death varies by age. There are no other pre-specified interactions between the treatment exposure of interest and the clinical variables, however, if an effect is found we will explore whether this varies according to calendar time (pre and post lockdown in the UK, 23rd of March). This investigation would depend on having a sufficient number of cases in our study population pre-lockdown.

### Secondary Objectives

The methodology for the secondary outcomes will be as described for the primary objectives above.

### Exploratory Objectives

If we detect a non-null association, in future work we will consider investigating this further through the use of a negative control outcome, as we hypothesise that any effect of ICS on COVID-19 outcomes may be specific to COVID-19 and may not be expected to be seen with other viral respiratory infections. We have hypothesised that influenza-like illness during the 3 flu seasons from 2016 to 2019 may be a suitable negative control. However, any such analyses will be dependent on data availability from previous calendar years, which is not established at the time of locking v1.0 of the protocol. If there is a non-null association and this analysis is possible to implement, this will be reflected in a protocol amendment with details regarding the identification of a suitable negative control outcome, as well as refinements regarding this part of the study design.

Secondly, for any non-null association, with 95% confidence intervals wholly above or below 1 in the primary analysis, we will conduct a quantitative bias analysis. This will estimate how strong unmeasured confounding would need to be in order to explain the association. We will use Ding and Vanderweele's e-value formulae, alongside probabilistic bias analysis, to estimate how strongly associated one or more unmeasured confounders would need to be with exposure and outcome to fully explain the observed association.

A final exploratory objective relates to defining exposure variables based on more detailed dosing instructions as well as estimated adherence. In the first planned analysis, we have grouped low and medium dose ICS together as a readily available dosing instruction decode facilitating assignment of low or medium ICS dose is not currently available. In future work, if/when this becomes available we aim to further separate low and medium dose. Similarly, in later work a secondary definition of exposure categories, based around likely treatment adherence will be defined if possible. The rationale for this is that any signal regarding a causal protective effect should be stronger in a more adherent group, assuming adherence doesn't change during the pandemic. Preliminary exposure groups, based on adherence, are listed below for the two populations:

#### Asthma Cohort

- SABA only (baseline)
- Any steroid with high adherence ( $\geq 70\%$  by proportion of days covered in the previous 12 months)
- Any steroid with low adherence ( $< 70\%$  by proportion of days covered in the previous 12 months)
- Other

#### COPD Cohort

- Non-ICS based treatment (baseline)
- ICS based high adherence ( $\geq 70\%$  in previous 12 months)
- ICS based low adherence ( $< 70\%$  in previous 12 months)

### **Sensitivity Analyses Objectives**

We will also conduct a number of sensitivity analyses to evaluate the robustness of our results. This is anticipated to include:

1. Re-run the analyses using COVID-19 specific death in ONS as the outcome
2. For COPD analyses: redefine exposure categories separating dual and triple ICS therapy
3. For asthma analyses: Classify patients exposed to both low/medium and high ICS doses as receiving high dose ICS
4. For asthma analyses: Redefine the asthma population as anyone with an asthma record in the prior 3 years OR a record of asthma at any prior time, and receiving a prescription for an asthma medication in the last 4 months.

It should be noted that more sensitivity analyses may be added based on the initial results of analyses. These will be clearly marked as post-hoc analyses in any reporting of the results.

## Table Shells

Note: Table shells are presented for the asthma population, and the primary objectives only. The tables will be adapted and repeated for the COPD population and for secondary objectives as required. Figures are not included as shells.

**Figure 1: Flowchart of Patients**

**Table 1: Descriptive Characteristics**

		Total	SABA	ICS		Other
				<i>Medium/Low</i>	<i>High</i>	
<b>Total</b>						
<b>Age</b>	18-<40					
	40-<50					
	50-<60					
	60-<70					
	70-<80					
	80+					
<b>Gender</b>	Female					
	Male					
<b>BMI</b>	<18.5					
	18.5-24.9					
	25-29.9					
	30-34.9					
	35-39.9					
	Missing					
<b>Ethnicity</b>	White					
	Mixed					
	Asian or Asian British					
	Black					

	Other					
	Missing					
<b>IMD</b>	1 (least deprived)					
	2					
	3					
	4					
	5 (most deprived)					
<b>Smoking</b>	Never					
	Current					
	Former					
	Missing					
<b>Comorbidities</b>	Hypertension					
	Heart Failure					
	Other Heart Disease					
	Diabetes					
	Cancer					
	Immunosuppression					
	CKD					
<b>GP consultations</b>	Median, IQR					
	Min, Max					
<b>Vaccination</b>	Flu					
	Pneumococcal					
<b>Medications</b>	Insulin					
	Statin					
	Oral Steroids					

## Figure 2: Kaplan-Meier Plot of Time to in-hospital COVID-19 death, stratified by Treatment

[Note: Including number under follow-up at each time-point, for each treatment category]

**Table 2: Hazard Ratios (HRs) and 95% confidence intervals (CI) for in-hospital COVID-19 death**

		N (%) with the outcome	Unadjusted	Age-Sex Adjusted	Fully Adjusted
			HR (95% CI)	HR (95% CI)	HR (95% CI)
<b>Treatment</b>	<b>SABA only (reference)</b>		1.00	1.00	1.00
	ICS (low/medium dose)				
	ICS (high dose)				
	Other				

**Figure 3: Forest Plots of Hazard Ratios (HRs) and 95% confidence intervals (CI) for in-hospital COVID-19 death**



## Strengths and Limitations

The strengths of this study will include the size of the source population: openSAFELY represents one of the largest EHR databases in Europe. This will allow analyses to have as high power as is possible during this stage of the pandemic. The primary outcome, death as recorded in CPNS, is also being recorded and analysed in near real-time, which will allow the number of outcome events to be maximised and, again, ensuring analyses are as well powered as possible. The richness of the EHR will allow us to characterise patients' medical history with a relatively high degree of accuracy, as we will not be relying on data being collected during the pandemic to characterise comorbidities. This should allow us to better control for confounding by indication compared to studies conducted solely in the hospital setting. Other strengths will include the pre-specified objectives and analysis plan, which will clearly allow readers to see which hypotheses and analyses were planned in advance. Finally, all source code that is used both to define the study population and run the analysis will be made publicly available for other researchers to both re-use and scrutinize.

However, there are also limitations which should be borne in mind when interpreting any results. Notably these limitations would tend to apply to any study addressing this question using observational data, and are not unique to this study. Firstly, although we will attempt to reduce confounding by indication by choosing a restricted study population, using active comparators where available as well as adjusting for potentially important confounders, we cannot rule out that confounding by indication will remain after this – either due to variables we have not measured, or those we have measured imperfectly. Confounding by indication is a particular concern in the asthma population, where we anticipate most patients will be treated with an ICS, though we will be able to take advantage of the use of SABA only in patients who ought to be prescribed an ICS. Nonetheless, based on early analyses from the openSAFELY.org risk factor analyses, we would expect patients with more severe asthma to have worse outcomes than those with less severe asthma<sup>6</sup>. If our analyses are subject to confounding by indication due to asthma severity, we might therefore expect to observe an increasing risk of death among patients prescribed ICS compared to those prescribed SABA. The direction of this bias may therefore cause us to miss a true protective effect of ICS, should one exist. However, given how little we know about COVID-19 disease, and the unclear nature of individual patient behaviour changes during the pandemic, it is also possible that biases could operate in different directions. Treatment group comparability may be closer for the COPD cohort where we rely on some degree of patient/prescriber choice driving the decision over ICS based and non-ICS based therapy. However, we are aware that if NICE guidance on COPD treatment is very closely adhered to, the exposure groups may differ in important ways and our comparative analysis relies on a degree of non-guidance based prescribing. Comparisons of baseline characteristics will help us explore this, as will the secondary exposure definition where dual and triple ICS-based regimens are separated. The expectation here is that those receiving triple therapy are likely to have more severe COPD than those receiving dual therapy. To aid the interpretation of our results, for all detected associations we will quantify the strength an unmeasured confounder or group of unmeasured/imperfectly measured confounders would need to have to remove the observed association using so-called e-values.

A second limitation is that hospital death due to COVID-19 is a “moving” outcome over time, as the people tested for COVID-19 has changed with the changing case definition and

national testing strategy. However, it should be noted that CPNS is restricted to inpatient deaths only, and patients sick enough to require hospital admission have always been prioritised for receipt of COVID-19 testing. CPNS death as an outcome may therefore be less susceptible to changes over time compared to some of our secondary outcomes, such as A&E presentation. Any changes over time in the relationship between the exposures of interest and the outcomes will be evaluated as part of checking the assumption of proportional hazards in the Cox regression models. Deviations from proportional hazards will be considered and explored carefully, as we would not expect a true pharmacological association to vary over time, even as the pandemic progresses. Nonetheless, there may be reasons we cannot detect a true association during the different stages of the pandemic. For example, if asthmatics are shielding as the pandemic progresses, there may be fewer events among these patients as time goes on. Although the relative effect of the exposure should remain the same, the resulting lack of power could impact the precision by which this can be estimated.

CPNS death will be used as the primary outcome as this is most up to date. However, it should be noted that this does not include deaths outside the hospital setting, such as deaths occurring in care homes. Deaths occurring outside the hospital have been given greater attention as the pandemic has progressed, and the exclusion of these from our outcome will lead to an underestimate of the absolute risk of death. If patients that are dying in care homes are more or less likely to be exposed to certain types of asthma or COPD medications due to reasons that we cannot capture in the data, this can introduce bias in the results. We will address this in a sensitivity analysis using ONS death as the outcome.

Our analyses are also subject to risk of exposure misclassification. We have a broad exposure definition to capture patients who may have stockpiled medication prior to lockdown, however, we do not know whether or not patients with these prescriptions were truly taking the medications as prescribed. In addition, we did not have readily available information on doses for asthma medications, which meant that we had to categorise low and medium dose ICS together.

Given the inherent limitations of the study design, our results should be taken as hypothesis generating. Multiple studies of different designs, in different populations, will be needed before a conclusive answer relating to the impact of ICS exposure on COVID-19 infection risk and outcomes can be given.

## References

1. COVID-19 Map. *Johns Hopkins Coronavirus Resource Center* <https://coronavirus.jhu.edu/map.html>. Accessed 8th of May 2020.
2. Coronavirus (COVID-19) cases in the UK. <https://coronavirus.data.gov.uk/>. Accessed 8th of May 2020.
3. Guan, W. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N. Engl. J. Med.* **0**, null (2020).
4. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* **395**, 507–513 (2020).
5. Garg, S. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, (2020).
6. The OpenSAFELY Collaborative, T. O. *et al.* OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *medRxiv* 2020.05.06.20092999 (2020) doi:10.1101/2020.05.06.20092999.
7. Halpin, D. M. G., Faner, R., Sibila, O., Badia, J. R. & Agusti, A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? *Lancet Respir. Med.* **0**, (2020).
8. Zhang, J. *et al.* Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* **n/a**,.
9. Docherty, A. B. *et al.* Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. *medRxiv* 2020.04.23.20076042 (2020) doi:10.1101/2020.04.23.20076042.
10. Halpin, D. M. G., Singh, D. & Hadfield, R. M. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. *Eur. Respir. J.* (2020) doi:10.1183/13993003.01009-2020.
11. Corticosteroids - inhaled - NICE CKS. <https://cks.nice.org.uk/corticosteroids-inhaled>.
12. Suissa, S., Patenaude, V., Lapi, F. & Ernst, P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. *Thorax* **68**, 1029–1036 (2013).
13. Ernst, P., Gonzalez, A. V., Brassard, P. & Suissa, S. Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and the Risk of Hospitalization for Pneumonia. *Am. J. Respir. Crit. Care Med.* **176**, 162–166 (2007).

14. Crim, C. *et al.* Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. *Eur. Respir. J.* **34**, 641–647 (2009).
15. Matsuyama, S. *et al.* The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. *bioRxiv* 2020.03.11.987016 (2020) doi:10.1101/2020.03.11.987016.
16. Yamaya, M. *et al.* Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. *Respir. Investig.* (2020) doi:10.1016/j.resinv.2019.12.005.
17. Protective Role of Inhaled Steroids for COVID-19 Infection - Full Text View - ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT04331054>.
18. A Trial of Ciclesonide in Adults With Mild COVID-19 - Full Text View - ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT04330586>.
19. Bloom, C. I. *et al.* Exacerbation risk and characterisation of the UK's asthma population from infants to old age. *Thorax* **73**, 313–320 (2018).
20. Nissen, F. *et al.* Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). *BMJ Open* **7**, e017474 (2017).
21. Overview | Chronic obstructive pulmonary disease in over 16s: diagnosis and management | Guidance | NICE. <https://www.nice.org.uk/guidance/NG115>. Accessed 13th of May 2020
22. Asthma | British Thoracic Society | Better lung health for all. <https://brit-thoracic.org.uk/quality-improvement/guidelines/asthma/>. Accessed 13th of May 2020